RRM2
RRM2 (Ribonucleoside-diphosphate reductase subunit M2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Breast cancer and 5 more.
Overview
Provides the precursors necessary for DNA synthesis. Catalyses the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signalling.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Gemcitabine. Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.00, clinical 0.99).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RRM2 (Ribonucleoside-diphosphate reductase subunit M2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Breast cancer and 5 more.
- 1 · What it is
RRM2 (Ribonucleoside-diphosphate reductase subunit M2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Breast cancer and 5 more.
- 2 · What goes wrong in cancer
Provides the precursors necessary for DNA synthesis. Catalyses the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides.
- 3 · How drugs use it
No product in this corpus aims at RRM2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:10452 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P31350 (protein name, function text, keywords and locations (REST API)); CIViC gene RRM2 (1 evidence items, 0 assertions, 1 variants; diseases: Pancreatic Cancer (GraphQL API, CC0)); Open Targets ENSG00000171848 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.62, ovarian cancer 0.59, melanoma 0.58, acute lymphoblastic leukaemia 0.60, B-cell chronic lymphocytic leukaemia 0.59, non-Hodgkin lymphoma 0.60 (GraphQL API, CC0))
Biology
Provides the precursors necessary for DNA synthesis. Catalyses the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signalling. Location: Cytoplasm; Nucleus (UniProt). Locus 2p25.1 (HGNC).
- Lung cancer: Open Targets association 0.62 with lung cancer (MONDO_0008903)
- Leukaemia: Open Targets association 0.62 with leukaemia (MONDO_0005059)
- Breast cancer: Open Targets association 0.61 with breast cancer (MONDO_0007254)
- Non-Hodgkin lymphoma: Open Targets association 0.60 with non-Hodgkin lymphoma (MONDO_0018908)
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease
- Ovarian cancer: Open Targets association 0.59 with ovarian cancer (MONDO_0008170)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99; CIViC holds 1 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"RRM2" OR ABSTRACT:"RRM2" OR TITLE:"ribonucleotide reductase regulatory subunit M2" OR ABSTRACT:"ribonucleotide reductase regulatory subunit M2" OR TITLE:"Ribonucleoside-diphosphate reductase subunit M2" OR ABSTRACT:"Ribonucleoside-diphosphate reductase subunit M2" OR TITLE:"FLJ25102" OR ABSTRACT:"FLJ25102" OR TITLE:"C2orf48" OR ABSTRACT:"C2orf48") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RRM2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPOLD1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetPOLA2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLD2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLD3
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLD4
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLE2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLE3
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPRIM1
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).